HER2-Low Breast Cancer Can Be Visualized by HER2 PET
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.266101 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Renske Altena und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
TO THE EDITOR: We would like to comment on the letter from Seban et al. to the editor of The Journal of Nuclear Medicine in the July issue ([1][1]). The results from the DESTINY-Breast04 trial, receiving a standing ovation during the presidential symposium at the annual conference of the American
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Altena, R., Af Burén, S., Tran, T., & Axelsson, R. (2023). HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266101
Vancouver
Altena R, Af Burén S, Tran T, Axelsson R. HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.266101
BibTeX
@article{Altena2023,
author = {Altena, Renske and Af Burén, Siri and Tran, Thuy and Axelsson, Rimma},
title = {HER2-Low Breast Cancer Can Be Visualized by HER2 PET},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.266101}
}
EUVIMED